Cargando…

P926: ELEVATED SERUM LEVELS OF SOLUBLE B-CELL MATURATION ANTIGEN AS A PROGNOSTIC BIOMARKER FOR MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Du, Juan, Guo, Pei, Wang, Yun, He, Haiyan, Chen, Dongjian, Liu, Jin, Qiang, Wanting, Lu, Jing, Liang, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431008/ http://dx.doi.org/10.1097/01.HS9.0000970608.12462.49

Ejemplares similares

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL
por: Leypoldt, L., et al.
Publicado: (2022)

Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma
por: Wiedemann, Ádám, et al.
Publicado: (2023)

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
por: Ghermezi, Michael, et al.
Publicado: (2017)

926. Antibody Response to HPV Vaccination in Pediatric and Adolescent People Living with HIV (PLWH)
por: Al Hammoud, Roukaya, et al.
Publicado: (2020)

PB2104: SOLUBLE B-CELL MATURATION ANTIGEN AS A MONITORING MARKER FOR MULTIPLE MYELOMA
por: Wiedemann, Ádám, et al.
Publicado: (2023)

P838: EXOSOME MIRNAS PROFILING IN SERUM AND PROGNOSTIC EVALUATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Fang, Teng, et al.
Publicado: (2023)

926. COVID-19 Infections After SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients
por: Saharia, Kapil, et al.
Publicado: (2021)

Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma
por: Luo, Tiancheng, et al.
Publicado: (2020)

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: van de Donk, N., et al.
Publicado: (2023)

Single‐cell RNA‐seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma
por: He, Haiyan, et al.
Publicado: (2022)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
por: Einsele, H, et al.
Publicado: (2022)

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Popat, R, et al.
Publicado: (2022)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023)

P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
por: Manier, Salomon, et al.
Publicado: (2023)

Prognostic value of routinely assessed serum biomarkers in septic shock
por: Lafuente, E, et al.
Publicado: (2011)

The Landscape of Cytogenetic Aberrations in Light-Chain Amyloidosis with or without Coexistent Multiple Myeloma
por: He, Haiyan, et al.
Publicado: (2023)

P887: PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
por: Tamariz-Amador, Luis-Esteban, et al.
Publicado: (2023)

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Popat, R., et al.
Publicado: (2022)

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Martínez-López, J., et al.
Publicado: (2022)

Elevation of serum phosphorus, an early biomarker of acute kidney injury after cardiac sugery?
por: Ridolfo, J, et al.
Publicado: (2015)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma
por: Ma, Tiantian, et al.
Publicado: (2021)

Adult T-cell leukemia/lymphoma following elevation of serum levels of soluble cytokine receptors, sCD25 and sCD30
por: Takemoto, Shigeki, et al.
Publicado: (2014)

P845: DECIPHERING PLASMA CELL HETEROGENEITY AND TRANSCRIPTOME FEATURES IN POEMS SYNDROME USING SINGLE CELL RNA-SEQUENCING
por: He, Haiyan, et al.
Publicado: (2023)

Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model
por: Nakamura, M, et al.
Publicado: (2008)

Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018)

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
por: Lesokhin, A. M., et al.
Publicado: (2022)

P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lowther, D.E., et al.
Publicado: (2023)

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Sidana, Surbhi, et al.
Publicado: (2023)

P859: PROGNOSTIC IMPACT OF OPIOID USE PRIOR TO DIAGNOSIS OF MULTIPLE MYELOMA
por: Brieghel, Christian, et al.
Publicado: (2023)

Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
por: Fang, Yi, et al.
Publicado: (2021)

P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS
por: Barilà, G, et al.
Publicado: (2022)

Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia
por: Cheng, Wen, et al.
Publicado: (2015)

Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2022)

Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma
por: Łacina, Piotr, et al.
Publicado: (2022)

P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Attucci, I., et al.
Publicado: (2023)

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
por: Shrivastava, Trilok, et al.
Publicado: (2023)

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
por: Ma, Tiantian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m4m9k1qc4cljpk4kjg2in6h7cu